Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMS | P04818 | 1/20 | 0.41 |
| ▸ | ACHE | P22303 | 4/20 | 0.39 |
| ▸ | BCHE | P06276 | 3/20 | 0.39 |
| ▸ | FFAR2 | O15552 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.38 |
| ▸ | MMP13 | P45452 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4441921 | 1.00 | TYMS (0.41) | TYMSACHEBCHEFFAR2MEN1 | |
| SCHEMBL2351853 | 1.00 | TYMS (0.41) | TYMSACHEBCHEFFAR2MEN1 | |
| SCHEMBL2346142 | 0.89 | ALDH1A1 (0.43) | TYMSFFAR2MEN1KMT2AGPR119 | |
| SCHEMBL2587508 | 0.89 | FFAR2 (0.38) | TYMSFFAR2MEN1KMT2AGPR119 | |
| SCHEMBL4437760 | 0.89 | MAOA (0.43) | TYMSFFAR2MEN1KMT2AMAPK1 | |
| SCHEMBL2348191 | 0.89 | MAOA (0.43) | TYMSFFAR2MEN1KMT2AMAPK1 | |
| SCHEMBL20835488 | 0.88 | TYMS (0.48) | TYMSMEN1KMT2AGPR119 | |
| SCHEMBL2584143 | 0.87 | RIPK1 (0.46) | TYMSACHEBCHEGPR119ALDH1A1 | |
| SCHEMBL4437705 | 0.85 | DPP4 (0.39) | TYMSMEN1KMT2AGPR119ALDH1A1 | |
| SCHEMBL2351664 | 0.85 | DPP4 (0.39) | TYMSMEN1KMT2AGPR119ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100063065-A1 | THIOPHENE DERIVATIVES AS PPAR AGONISTS I | INPHARMATICA LIMITED (GB) | 2010-03-11 | — | — | US | disclosed |
| EP-1937663-A1 | THIOPHENE DERIVATIVES AS PPAR AGONISTS I | Inpharmatica Limited (GB) | 2008-07-02 | — | — | EP | disclosed |
| WO-2007036730-A9 | THIOPHENE DERIVATIVES AS PPAR AGONISTS I | INPHARMATICA LTD (GB) | 2008-06-19 | — | — | WO | disclosed |
| WO-2007036730-A1 | THIOPHENE DERIVATIVES AS PPAR AGONISTS I | INPHARMATICA LIMITED (GB) | 2007-04-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100063065-A1 | THIOPHENE DERIVATIVES AS PPAR AGONISTS I | PPARG, PPARD, PPARA | TYMS 1718/4885ACHE 3657/4885BCHE 3229/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.